Abstract
In the past decade, cancer stem cells (CSCs) have been isolated, characterized, and studied in a variety of cancers and they are believed to be responsible for tumor initiation and progression. Like normal stem cells, these cells retain self-renewal property and therefore, can differentiate into multiple tumor types. Despite this clinical importance, how CSCs are regulated and their exact pathological role are yet to be elucidated. Recent studies have shed light on the potential role of miRNAs in regulating CSCs. In this review, we summarize the current findings of miRNAs in the regulation of CSCs through different self-renewal pathways and the potential therapeutic implications of miRNAs in clinical settings by targeting CSCs.
Keywords: Cancer stem cells, MicroRNA, signaling pathways, self-renewal.
Current Pharmaceutical Design
Title:MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Volume: 20 Issue: 33
Author(s): Fei Xing, Kerui Wu and Kounosuke Watabe
Affiliation:
Keywords: Cancer stem cells, MicroRNA, signaling pathways, self-renewal.
Abstract: In the past decade, cancer stem cells (CSCs) have been isolated, characterized, and studied in a variety of cancers and they are believed to be responsible for tumor initiation and progression. Like normal stem cells, these cells retain self-renewal property and therefore, can differentiate into multiple tumor types. Despite this clinical importance, how CSCs are regulated and their exact pathological role are yet to be elucidated. Recent studies have shed light on the potential role of miRNAs in regulating CSCs. In this review, we summarize the current findings of miRNAs in the regulation of CSCs through different self-renewal pathways and the potential therapeutic implications of miRNAs in clinical settings by targeting CSCs.
Export Options
About this article
Cite this article as:
Xing Fei, Wu Kerui and Watabe Kounosuke, MicroRNAs in Cancer Stem Cells: New Regulators of Stemness, Current Pharmaceutical Design 2014; 20 (33) . https://dx.doi.org/10.2174/1381612820666140128210912
DOI https://dx.doi.org/10.2174/1381612820666140128210912 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Current Topics in Medicinal Chemistry Radioiodinated Agents for Imaging Multidrug Resistant Tumors
Medicinal Chemistry Animal Models of Carcinogenesis in Inflamed Colorectum: Potential Use in Chemoprevention Study
Current Drug Targets MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology Synthesis of 9-O-3-(1-piperazinyl/morpholinyl/piperidinyl)pentyl-berberines as Potential Antioxidant and Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Structures Required of Polyphenols for Inhibiting Advanced Glycation end Products Formation
Current Drug Metabolism The Role of Androgen Receptor Mutations in Prostate Cancer Progression
Current Genomics Group-sparse Modeling Drug-kinase Networks for Predicting Combinatorial Drug Sensitivity in Cancer Cells
Current Bioinformatics Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer
Current Signal Transduction Therapy Current Trends and Future Directions of Fluoroquinolones
Current Medicinal Chemistry Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Towards Characterization of the Human Urinary Peptidome
Combinatorial Chemistry & High Throughput Screening Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer
Current Cancer Drug Targets Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets